Citations

Clear

1526 citation(s) found for "Sun, Bo".

Genome-wide association study identifies high-impact susceptibility loci for HCC in North America
Hassan, Manal M. , Li, Donghui , Han, Younghun , Choi, Jiyeon , Kelley, Robin Kate , Bracci, Paige M. , Bucur, Roxana , Ghobrial, R. Mark , Santella, Regina M. , Nguyen, Mindie H. , Liu, Geoffrey , Parikh, Neehar D. , Wu, Hui‐Chen , El‐Serag, Hashem B. , Chang, Ping , Li, Yanan , Chun, Yun Shin , Lee, Sunyoung S. , Gu, Jian , Hawk, Ernest T. , Huff, Chad , Rashid, Asif , Amin, Hesham M. , Beretta, Laura , Wolff, Robert A. , Antwi, Samuel O. , Patt, Yehuda Z., Hwang, Lu‐Yu, Schmidt, Mikayla A. , White, Donna L. , Goss, John A. , Khaderi, Saira, Marrero, Jorge A. , Cigarroa, Francisco , Roberts, Lewis R. , Han, Younghun , Roberts, Lewis R , Antwi, Samuel O , Liu, Geoffrey , Parikh, Neehar D , Beretta, Laura , Gu, Jian , Byun, Jinyoung , Hatia, Rikita , Long, Erping , Cleary, Sean P. , Lok, Anna S. , Permuth, Jennifer B. , Yuan, Jian-Min , Singal, Amit G. , Jalal, Prasun K. , Kono, Yuko , Shah, Dimpy P. , Nguyen, Mindie H. , Kim, Richard D. , Li, Yanan, Sun, Ryan , Klein, Alison P. , Zhang, Karen , Shah, Pankil , Kaseb, Ahmed O , Amos, Christopher I.

Mayo Clinic

Hepatology | February 21, 2024 | Volume: 80 | Issue: 1 | Pages: 87-101

10.1097/hep.0000000000000800 | PMID 38381705 Get It

Background and Aims: Despite the substantial impact of environmental factors, individuals with a family history of liver cancer have an increased risk for HCC. However, genetic factors have not been studied systematically by genome-wide approaches in large numbers of individuals from European descent populations (EDP). Approach and Results: We conducted a 2-stage genome-wide association study (GWAS) on HCC not affected by HBV infections. A total of 1872 HCC cases and 2907 controls were included in the discovery stage, and 1200 HCC cases and 1832 controls in the validation. We analyzed the discovery and validation samples separately and then conducted a meta-analysis. All analyses were conducted in the presence and absence of HCV. The liability-scale heritability was 24.4% for overall HCC. Five regions with significant ORs (95% CI) were identified for nonviral HCC: 3p22.1, MOBP, rs9842969, (0.51, [0.40–0.65]); 5p15.33, TERT, rs2242652, (0.70, (0.62–0.79]); 19q13.11, TM6SF2, rs58542926, (1.49, [1.29–1.72]); 19p13.11 MAU2, rs58489806, (1.53, (1.33–1.75]); and 22q13.31, PNPLA3, rs738409, (1.66, [1.51–1.83]). One region was identified for HCV-induced HCC: 6p21.31, human leukocyte antigen DQ beta 1, rs9275224, (0.79, [0.74–0.84]). A combination of homozygous variants of PNPLA3 and TERT showing a 6.5-fold higher risk for nonviral-related HCC compared to individuals lacking these genotypes. This observation suggests that gene-gene interactions may identify individuals at elevated risk for developing HCC. Conclusions: Our GWAS highlights novel genetic susceptibility of nonviral HCC among European descent populations from North America with substantial heritability. Selected genetic influences were observed for HCV-positive HCC. Our findings indicate the importance of genetic susceptibility to HCC development.
Right Ventricular Assist Device Placement During Left Ventricular Assist Device Implantation Is Associated With Improved Survival
Crespo‐Diaz, Ruben , Mudy, Karol, Samara, Michael A., Sun, Benjamin , Hryniewicz, Katarzyna , Khan, Nadeem, Eckman, Peter

Mayo Clinic

ASAIO Journal | February 19, 2024 | Volume: 70 | Issue: 7 | Pages: 570-577

10.1097/mat.0000000000002160 | PMID 38373178 Get It

Right ventricular failure (RVF) is a significant cause of mortality in patients undergoing left ventricular assist device (LVAD) implantation. Although right ventricular assist devices (RVADs) can treat RVF in the perioperative LVAD period, liberal employment before RVF is not well established. We therefore compared the survival outcomes between proactive RVAD placement at the time of LVAD implantation with a bailout strategy in patients with RVF. Retrospectively, 75 adult patients who underwent durable LVAD implantation at our institution and had an RVAD placed proactively before LVAD implantation or as a bailout strategy postoperatively due to hemodynamically unstable RVF were evaluated. Patients treated with a proactive RVAD strategy had lower Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) and a higher proportion of these required temporary mechanical circulatory support (MCS) preoperatively. Preoperative hemodynamic profiling showed a low pulmonary artery pulsatility index (PAPi) score of 1.8 ± 1.4 and 1.6 ± 0.94 (p = 0.42) in the bailout RVAD and proactive RVAD groups, respectively. Survival at 3, 6, and 12 months post-LVAD implantation was statistically significantly higher in patients who received a proactive RVAD. Thus, proactive RVAD implantation is associated with short- and medium-term survival benefits compared to a bailout strategy in RVF patients undergoing LVAD placement.
Sorbs2 Deficiency and Vascular BK Channelopathy in Diabetes
Sun, Xiaojing , Lee, Hon-Chi , Lü, Tong , Lu, Tong

Mayo Clinic

Circulation Research | February 16, 2024 | Volume: 134 | Issue: 7 | Pages: 858-871

10.1161/circresaha.123.323538 | PMID 38362769 Get It

BACKGROUND: Vascular large conductance Ca 2+ -activated K + (BK) channel, composed of the α-subunit (BK-α) and the β1-subunit (BK-β1), is a key determinant of coronary vasorelaxation and its function is impaired in diabetic vessels. However, our knowledge of diabetic BK channel dysregulation is incomplete. The Sorbs2 (Sorbin homology [SoHo] and Src homology 3 [SH3] domains-containing protein 2), is ubiquitously expressed in arteries, but its role in vascular pathophysiology is unknown. METHODS: The role of Sorbs2 in regulating vascular BK channel activity was determined using patch-clamp recordings, molecular biological techniques, and in silico analysis. RESULTS: Sorbs2 is not only a cytoskeletal protein but also an RNA-binding protein that binds to BK channel proteins and BK-α mRNA, regulating BK channel expression and function in coronary smooth muscle cells. Molecular biological studies reveal that the SH3 domain of Sorbs2 is necessary for Sorbs2 interaction with BK-α subunits, while both the SH3 and SoHo domains of Sorbs2 interact with BK-β1 subunits. Deletion of the SH3 or SoHo domains abolishes the Sorbs2 effect on the BK-α/BK-β1 channel current density. Additionally, Sorbs2 is a target gene of the Nrf2 (nuclear factor erythroid-2-related factor 2), which binds to the promoter of Sorbs2 and regulates Sorbs2 expression in coronary smooth muscle cells. In vivo studies demonstrate that Sorbs2 knockout mice at 4 months of age display a significant decrease in BK channel expression and function, accompanied by impaired BK channel Ca 2+ -sensitivity and BK channel-mediated vasodilation in coronary arteries, without altering their body weights and blood glucose levels. Importantly, Sorbs2 expression is significantly downregulated in the coronary arteries of db/db type 2 diabetic mice. CONCLUSIONS: Sorbs2, a downstream target of Nrf2, plays an important role in regulating BK channel expression and function in vascular smooth muscle cells. Vascular Sorbs2 is downregulated in diabetes. Genetic knockout of Sorbs2 manifests coronary BK channelopathy and vasculopathy observed in diabetic mice, independent of obesity and glucotoxicity.
Persistent B Cell–Derived MHC Class II Signaling Is Required for the Optimal Maintenance of Tissue-Resident Helper T Cells
Son, Young Min , Cheon, In Su , Li, Chaofan , Sun, Jie , Sun, Jie , Li, Chaofan

Mayo Clinic

ImmunoHorizons | February 12, 2024 | Volume: 8 | Issue: 2 | Pages: 163-171

10.4049/immunohorizons.2300093 | PMID 38345472 Get It

Abstract Emerging studies have identified the critical roles of tissue-resident memory CD8+ T (TRM) and B (BRM) cells in the protection against mucosal viral infections, but the underlying mechanisms regulating robust development of TRM and BRM cells remain incompletely understood. We have recently shown that tissue-resident helper CD4+ T (TRH) cells, developed following influenza virus infection, function to sustain the optimal maintenance of TRM and BRM cells at the mucosal surface. In this study, we have explored the cellular and molecular cues modulating lung TRH persistence after influenza infection in C57BL/6 mice. We found that TRH cells were colocalized in tertiary lymphoid structures (TLSs) with local B cells. Abolishing TLSs or the depletion of B cells impaired lung TRH cell numbers. Of note, we found that persistent TCR signaling is needed for the maintenance of TRH cells after the clearance of infectious influenza virus. Furthermore, selective ablation of B cell–derived MHC class II resulted in partial reduction of lung TRH cell number after influenza infection. Our findings suggest that the interaction between lung-resident TRH cells and B cells, along with persistent Ag stimulation, is required to maintain TRH cells after respiratory viral infection.
Ultrahigh frequencies of peripherally matured LGI1- and CASPR2-reactive B cells characterize the cerebrospinal fluid in autoimmune encephalitis
Theorell, Jakob , Harrison, Ruby , Williams, Robyn , Raybould, Matthew I. J. , Zhao, Meng , Fox, Hannah , Fower, Andrew , Miller, Georgina, Wu, Zoe Y., Browne, Eleanor , Mgbachi, Victor , Mopuri, Rohini , Waters, Patrick , Makuch, Mateusz , Irani, Sarosh R. , Sun, Bo , Deane, Charlotte M , Handel, Adam , Irani, Sarosh R , Waters, Patrick J , Harrison, Ruby , Fox, Hannah , Zhao, Meng , Williams, Robyn L , Miller, Georgina, Sun, Bo , Li, Ying, Handel, Adam E.

Mayo Clinic

Proceedings of the National Academy of Sciences | February 6, 2024 | Volume: 121 | Issue: 7 | Pages: No page available

10.1073/pnas.2311049121 | PMID 38319973 Get It

Intrathecal synthesis of central nervous system (CNS)-reactive autoantibodies is observed across patients with autoimmune encephalitis (AE), who show multiple residual neurobehavioral deficits and relapses despite immunotherapies. We leveraged two common forms of AE, mediated by leucine-rich glioma inactivated-1 (LGI1) and contactin-associated protein-like 2 (CASPR2) antibodies, as human models to comprehensively reconstruct and profile cerebrospinal fluid (CSF) B cell receptor (BCR) characteristics. We hypothesized that the resultant observations would both inform the observed therapeutic gap and determine the contribution of intrathecal maturation to pathogenic B cell lineages. From the CSF of three patients, 381 cognate-paired IgG BCRs were isolated by cell sorting and scRNA-seq, and 166 expressed as monoclonal antibodies (mAbs). Sixty-two percent of mAbs from singleton BCRs reacted with either LGI1 or CASPR2 and, strikingly, this rose to 100% of cells in clonal groups with ≥4 members. These autoantigen-reactivities were more concentrated within antibody-secreting cells (ASCs) versus B cells ( P < 0.0001), and both these cell types were more differentiated than LGI1- and CASPR2-unreactive counterparts. Despite greater differentiation, autoantigen-reactive cells had acquired few mutations intrathecally and showed minimal variation in autoantigen affinities within clonal expansions. Also, limited CSF T cell receptor clonality was observed. In contrast, a comparison of germline-encoded BCRs versus the founder intrathecal clone revealed marked gains in both affinity and mutational distances ( P = 0.004 and P < 0.0001, respectively). Taken together, in patients with LGI1 and CASPR2 antibody encephalitis, our results identify CSF as a compartment with a remarkably high frequency of clonally expanded autoantigen-reactive ASCs whose BCR maturity appears dominantly acquired outside the CNS.
Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study
Samples, Laura , Fakhri, Bita , Khajavian, Sirin, Spurgeon, Stephen E. , Stephens, Deborah M. , Skarbnik, Alan P , Mato, Anthony R. , Broome, Catherine M. , Gopal, Ajay K. , Smith, Stephen D. , Lynch, Ryan C. , Rainey, Magdalena A., Barrett-Campbell, Odeth, Hemond, Emily, Malakhov, Nikita , Rao, Danielle, Shakib-Azar, Mehrdad, Morrigan, Beth, Chauhan, Ayushi , Plate, Thomas , Gooley, Ted, Ryan, Kellie, Hill, Brian T. , Pongas, Georgios , Allan, John N. , Cheng, Richard K. , Ujjani, Chaitra S. , Fakhri, Bita , Stephens, Deborah M , Gopal, Ajay , Smith, Stephen D , Rainey, Magdalena , Tsang, Mazie , Chauhan, Ayushi , Lansigan, Frederick , Parikh, Sameer A , Roeker, Lindsey , Allan, John N , Cheng, Richard , Ujjani, Chaitra , Voutsinas, Jenna M. , Kim, Myung Sun , Tsang, Mazie , Ermann, Daniel A. , Lansigan, Frederick , Parikh, Sameer A. , Roeker, Lindsey E. , Shadman, Mazyar

Mayo Clinic

Blood Advances | February 5, 2024 | Volume: 8 | Issue: 9 | Pages: 2085-2093

10.1182/bloodadvances.2023011569 | PMID 38315043 Get It

Abstract Although Bruton tyrosine kinase inhibitors (BTKis) are generally well tolerated and less toxic than chemotherapy alternatives used to treat lymphoid malignancies, BTKis like ibrutinib have the potential to cause new or worsening hypertension (HTN). Little is known about the optimal treatment of BTKi-associated HTN. Randomly selected patients with lymphoid malignancies on a BTKi and antihypertensive drug(s) and with at least 3 months of follow-up data were sorted into 2 groups: those diagnosed with HTN before BTKi initiation (prior-HTN), and those diagnosed with HTN after BTKi initiation (de novo HTN). Generalized estimating equations assessed associations between time varying mean arterial pressures (MAPs) and individual anti-HTN drug categories. Of 196 patients included in the study, 118 had prior-HTN, and 78 developed de novo HTN. Statistically significant mean MAP reductions were observed in patients with prior-HTN who took β blockers (BBs) with hydrochlorothiazide (HCTZ), (−5.05 mmHg; 95% confidence interval [CI], 10.0 to −0.0596; P = .047), and patients diagnosed with de novo HTN who took either an angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) with HCTZ (−5.47 mmHg; 95% CI, 10.9 to −0.001; P = .05). These regimens also correlated with the greatest percentages of normotensive MAPs. Treatment of HTN in patients taking a BTKi is challenging and may require multiple antihypertensives. Patients with prior-HTN appear to benefit from combination regimens with BBs and HCTZ, whereas patients with de novo HTN appear to benefit from ACEi/ARBs with HCTZ. These results should be confirmed in prospective studies.
The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement
Hagström, Hannes , Adams, Leon A. , Duseja, Ajay , Grønbæk, Henning , Jepsen, Peter , Kanwal, Fasiha , Newsome, Philip N. , Rinella, Mary E. , Schattenberg, Jörn M. , Simon, Tracey G. , Tapper, Elliot B. , Yılmaz, Yusuf , Zelber‐Sagi, Shira , Åberg, Fredrik , Lazarus, Jeffrey V. , Lazarus, Jeffrey V , Newsome, Philip N , Schattenberg, Jörn M , Rinella, Mary , Yilmaz, Yusuf , Hagström, Hannes , Allen, Alina M. , Byrne, Christopher D. , Chang, Yoosoo , Ismail, Mona Hassan , Kramer, Jennifer R. , Loomba, Rohit , Mark, Henry E. , Rowe, Ian A , Ryu, Seungho , Sanyal, Arun J. , Serper, Marina , Sheron, Nick , Spearman, C Wendy , Villota‐Rivas, Marcela , Wild, Sarah H. , Wong, Vincent Wai‐Sun

Mayo Clinic

Hepatology Communications | February 5, 2024 | Volume: 8 | Issue: 2 | Pages: No page available

10.1097/hc9.0000000000000386 | PMID 38315102 Get It

Background: Following the adoption of new nomenclature for steatotic liver disease, we aimed to build consensus on the use of International Classification of Diseases codes and recommendations for future research and advocacy. Methods: Through a two-stage Delphi process, a core group (n = 20) reviewed draft statements and recommendations (n = 6), indicating levels of agreement. Following revisions, this process was repeated with a large expert panel (n = 243) from 73 countries. Results: Consensus ranged from 88.8% to 96.9% (mean = 92.3%). Conclusions: This global consensus statement provides guidance on harmonizing the International Classification of Diseases coding for steatotic liver disease and future directions to advance the field.
Dynamic Prognosis Prediction for Patients on DAPT After Drug‐Eluting Stent Implantation: Model Development and Validation
Li, Fang , Rasmy, Laila , Xiang, Yang , Feng, Jingna , Abdelhameed, Ahmed , Hu, Xinyue , Sun, Zenan , Aguilar, David , Dhoble, Abhijeet , Du, Jingcheng , Wang, Qing , Zhang, Xinyuan , Xie, Ziqian , Nian, Yi , He, Jianping , Zhou, Yujia , Li, Jianfu , Prosperi, Mattia , Bian, Jiang , Zhi, Degui , Niu, Shuteng , Dang, Yifang , Zhang, Xinyuan , Xie, Ziqian , Nian, Yi , He, JianPing , Zhou, Yujia , Li, Jianfu , Prosperi, Mattia , Bian, Jiang , Zhi, Degui , Tao, Cui , Sun, Zenan , Li, Fang , Niu, Shuteng , Dang, Yifang , Tao, Cui

Mayo Clinic

Journal of the American Heart Association | January 31, 2024 | Volume: 13 | Issue: 3 | Pages: No page available

10.1161/jaha.123.029900 | PMID 38293921 Get It

Background The rapid evolution of artificial intelligence (AI) in conjunction with recent updates in dual antiplatelet therapy (DAPT) management guidelines emphasizes the necessity for innovative models to predict ischemic or bleeding events after drug‐eluting stent implantation. Leveraging AI for dynamic prediction has the potential to revolutionize risk stratification and provide personalized decision support for DAPT management. Methods and Results We developed and validated a new AI‐based pipeline using retrospective data of drug‐eluting stent‐treated patients, sourced from the Cerner Health Facts data set (n=98 236) and Optum's de‐identified Clinformatics Data Mart Database (n=9978). The 36 months following drug‐eluting stent implantation were designated as our primary forecasting interval, further segmented into 6 sequential prediction windows. We evaluated 5 distinct AI algorithms for their precision in predicting ischemic and bleeding risks. Model discriminative accuracy was assessed using the area under the receiver operating characteristic curve, among other metrics. The weighted light gradient boosting machine stood out as the preeminent model, thus earning its place as our AI‐DAPT model. The AI‐DAPT demonstrated peak accuracy in the 30 to 36 months window, charting an area under the receiver operating characteristic curve of 90% [95% CI, 88%–92%] for ischemia and 84% [95% CI, 82%–87%] for bleeding predictions. Conclusions Our AI‐DAPT excels in formulating iterative, refined dynamic predictions by assimilating ongoing updates from patients' clinical profiles, holding value as a novel smart clinical tool to facilitate optimal DAPT duration management with high accuracy and adaptability.
P433 Short-term outcomes of surgical treatment in primary ileocecal Crohn’s disease patients. Results of Crohn’s(urg) study, multicenter, retrospective, comparative analysis between indications for luminal and complicated phenotype
Bislenghi, Gabriele , D’Hoore, André , Juachon, Patrizia, Harsløf, Sanne , Gomez, Joanne Michelle D. , Merchea, Amit , Shacker, A, Gallostra, M Marti, Maruyana, B Yuki, Garoufalia, Zoe , Zhihui, C, Rrupa, Djana , Haanappel, Anouck , Giorgi, Lorenzo , Avellaneda, Nicolás , Pellino, Gianluca , Maroli, Annalisa , Tottrup, A, Colpaert, J, Giorgi, L, Overstraeten, Anthony de Buck van , Olivera, Pablo Andres , Gomez, J, Holubar, Stefan D. , Lincango-Naranjo, Eddy , Steele, Scott R. , Gallostra, M Marti, Kraft, Miquel , Kotze, Paulo Gustavo , Wexner, Steven D. , Zhihui, C, Hahnloser, Dieter , Buskens, Christianne Johanna , Warusavitarne, Janindra H. , Williams, K, Christensen, Peter , Spinelli, Antonino

Mayo Clinic

Journal of Crohn's and Colitis | January 24, 2024 | Volume: 18 | Issue: Supplement_1 | Pages: i881-i883

10.1093/ecco-jcc/jjad212.0563 Get It

Abstract Background Recent evidence challenges the current standard of offering surgery to patients with ileocecal Crohn’s disease only when they present complications of the disease. Methods A retrospective, multicenter comparative analysis was performed including patients operated for primary ileocecal CD at 12 referral centers. Patients were divided in 2 groups, according to indication of surgery for inflammatory (ICD) or complicated (CCD) phenotype. Short-term results were compared. Patients operated on for primary isolated ileocaecal CD (last 50 cm of the terminal ileum and cecum), either for predominantly inflammatory phenotype or for complications of the disease (stricturing or fistulizing pattern), between January 2012 - December 2021 were considered eligible to participate in this study. Patients with previous abdominal procedures for CD, and patients who had activity of the disease in other intestinal segments other than the ileocaecal region at the time of surgery, were excluded from the study. Results 2013 patients were included, 291 (14.5%) in the ICD group. No differences were found between groups in time from diagnosis to surgery or in the levels of exposure to biologic drugs before indication of surgery. CCD patients had higher rates of low BMI, anemia (40.9 vs. 27%, p: &lt; 0.001), and low albumin (11.3 vs. 2.6%, p: &lt; 0.001). CCD patients had longer operations, lower rates of laparoscopic approach (84.3 vs. 93.1%, p: 0.001), and higher conversion rates (9.3 vs. 1.9%, p: &lt; 0.001). CCD had longer hospital stay and higher postoperative complication rates (26.1 vs. 21.3%, p: 0.083). Anastomotic leakage and reoperations were also more frequent in this group. More patients in the CCD group required an extended bowel resection (14.1 vs. 8.3%, p: 0.017). In multivariate analysis, CCD was associated with prolonged surgeries (OR: 3.44, p: 0.001) and requirements of multiple intraoperative procedures (OR: 8.39, p: 0.030). Conclusion Indication of surgery in patients who present an inflammatory phenotype of CD was associated with better outcomes when compared to patients operated on for complications of the disease, without a difference between groups in time from diagnosis to surgery.
The Global Evolution of Inflammatory Bowel Disease across Four Epidemiologic Stages
Hracs, Lindsay , Gorospe, Julia, Buie, Michael , Quan, Joshua , Goddard, Quinn , Caplan, Léa , Markovinović, Ante , Abbey, Yvonne , Abdullah, Murdani , Balderramo, Domingo , Bernstein, Çharles N. , Burisch, Johan , Chong, Vui Heng , Dotan, Iris , Ouali, Sara El , Forss, Anders, Dao, Hang Viet , Baños, Fabián Juliao , Kaibullayeva, Jamilya , Kobayashi, Taku , Miao, Yinglei , Ng, Ka Kei , Olén, Ola , Simadibrata, Marcellus , Sun, Yang , Turner, Dan , Vergara, Beatriz, Wei, Shu Chen, Yang, Suk‐Kyun , Kobayashi, Taku , Kaplan, Gilaad G. , Windsor, Joseph W. , Cummings, Michael K. , Coward, Stephanie B. , Williamson, Tyler S. , Abreu, María T. , Ahuja, Vineet , Ali, Raja Affendi Raja , Altuwaijri, Mansour A. , Banerjee, Rupa , Benchimol, Eric I. , Bernstein, Charles Noah , Brunet, Eduard , Dutta, Usha , Forbes, Angela J. , Forss, Anders, Gearry, Richard B. , Hartono, Juanda Leo , Hilmi, Ida Normiha , Hodges, Phoebe , Jones, Gareth‐Rhys , Kelly, Paul , Kotze, Paulo Gustavo , Lakatos, Péter L. , Lees, Charlie W. , Limsrivilai, Julajak , Lo, Bobby Zhao Sheng , Loftus, Edward V. , Ludvigsson, Jonas F. , Mak, Joyce Wing Yan , Okabayashi, Shinji , Panaccione, Remo , Paudel, Mukesh Sharma , Quaresma, Abel Botelho , Rubin, David T. , Suzuki, Hidekazu , Toro, Martín , Wei, Shu Chen, Yamamoto-Furusho, Jesus , Ng, Siew C.

Mayo Clinic

No container title available | January 23, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3846147/v1 Get It

Abstract During the 20th century, inflammatory bowel disease (IBD) was considered a disease of early-industrialized regions in North America, Europe, and Oceania. At the turn of the 21st century, incidence of IBD increased in newly-industrialized and emerging regions in Africa, Asia, and Latin America, while prevalence in early-industrialized regions started to grow steadily. Changes in incidence and prevalence denote evolution of IBD across four epidemiologic stages: Stage 1 (Emergence), characterized by low incidence and prevalence; stage 2 (Acceleration in Incidence), characterized by rapidly rising incidence and low prevalence; and stage 3 (Compounding Prevalence), characterized by decelerating, plateauing, or declining incidence and steadily rising prevalence. A fourth stage (Prevalence Equilibrium) has been proposed where the slope of prevalence plateaus due to shifting demographics of an aging IBD population, but it has not yet been evidenced. To date, these stages have been theoretical without specific incidence/prevalence indicators defining transition points. Using real-world data from 490 population-based studies comprising 80 global regions and spanning over a century (1920–2023), we show spatiotemporal transitions across stages 1–3 and model transition towards stage 4. Understanding the evolution of IBD across epidemiologic stages allows healthcare systems to better prepare for the future worldwide burden of IBD.